Floatz logo

VIPIVOTIDE TETRAXETAN

Diffuse Hemispheric Glioma, H3 G34-mutant

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Diffuse Hemispheric Glioma, H3 G34-mutant cohort.

Asset / SponsorPhaseRating
Ribociclib
Nationwide Children's Hospital
Phase 2CCC
Everolimus
Nationwide Children's Hospital
Phase 2CCC
Pegargiminase
Sabine Mueller, MD, PhD
Phase 1/2CCC
Defactinib
Institute of Cancer Research, United Kingdom
Phase 1/2CC
Avutometinib
Institute of Cancer Research, United Kingdom
Phase 1/2CC

View all 9 →

Same molecule, other indications

VIPIVOTIDE TETRAXETAN is also rated in:

prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
67 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →